Herpes Cure Research Vaccine
"We decided to take an approach that runs counter to most of the tactics used by other scientists-and we seem to have cracked the code.". The study will also assess the vaccines impact on viral shedding, the process by which the virus can spread between people. Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. The vaccine - called GEN-003 and developed by Genocea Biosciences - is a T cell-enabled therapeutic vaccine designed to reduce the duration and severity of clinical symptoms associated with genital herpes and control transmission of the causative organism.
Simplirix candidate on disappointing data. At herpes the six-month time point all the participants in the study reported reductions in lesions - including those in the placebo group - and it was not genital possible to show a difference between the vaccine and control. Grant For HSV-2 Vaccine Program, Grant for HSV-2 Vaccine Program (PDF GenVec and Partners Get niaid Backing.
HSV Article CelSci Leaps Type of research 12month data is due for publication in the coming weeks.
Genital herpes is a recurrent, lifelong viral infection research and while symptoms can acute be managed with antiviral drugs such as valaciclovir or famciclovir, patients tend to suffer recurrent outbreaks, in some cases several times a year.
A vaccine that could free patients with genital herpes from lifelong drug treatment to control outbreaks has shown promise in a phase II trial. Keep up-to-date with new trials and treatment research. Being pregnant with herpes may also increase the chances of miscarriage, and HSV-2 infection is believed to make HIV much easier to contract. If approved, GEN-003 would be the first therapeutic vaccine to address genital herpes - or indeed any infectious disease - and Genocoa has previously predicted that it could become a 1bn product if brought to market. University of California, Irvine Professor. Their specially designed vaccine completely protected mice from the two major types of the disease, herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). Type of research HSV2 Vaccine, more information, herpes Vaccine, Bill Halford Awarded 400,000 grant, SIU Med School Receives NIH Grant to Study.
According to Zeena Nawas of the Center for Clinical Studies in Houston, Texas, who presented the results at the AAD meeting, this was a clinically relevant reduction and should reduce transmission of the virus. Type of research HSV2 Vaccine, more information. Other companies working on HSV-2 vaccines include Sanofi/Immune Design, Agenus, Tomegavax and Australian company Admedus, which has also just reported preliminary phase II data on its candidate. Herpes Vaccine Research, bioVex, Biotechnology Company, type of research HSV2 Vaccine A Phase 1 study commenced in February 2010. After the six months follow-up, there was an average 58 reduction in viral shedding.
Potential New Herpes Treatments in Clinical Trial. Efforts to develop an effective vaccine for HSV2 have resulted in a string of failures.
Experimental Herpes Vaccine Passes Early Mice Trials Are
In rare cases, HSV-1 can even cause a dangerous and often fatal swelling of the brain. The complete protection against both HSV-1 and HSV-2 is clinically relevant, as HSV-1 has emerged as the more common cause of genital disease in the developed world, the authors wrote. HSV is spread when patients have symptoms, so a key goal is to prevent outbreaks occurring.